Cusabio Organism Recombinants

Abstract

The discoveries of the double-stranded structure of DNA and the development of recombinant DNA technology sparked a revolution in industrial microbiology. Traditional industrial microbiology merged with molecular biology to produce improved organism recombinant processes for the industrial production of primary and secondary metabolites, biopharmaceutical proteins, and industrial enzymes. New genetic techniques such as metabolic engineering, combinatorial biosynthesis and molecular breeding techniques and their modifications are greatly contributing to the development of improved industrial processes.

Furthermore, functional genomics, proteomics and metabolomics are being exploited for the discovery of new small molecules valuable for medicine, as well as enzymes for catalysis. Sequencing of industrial microbial genomes is ongoing, which bodes well for future process improvement and the discovery of new industrial products.

Keywords:

antibiotics, antitumor agents, biopharmaceuticals, hypocholesterolemic agents, enzymes, genetic recombination, industrial products, primary metabolites, secondary metabolites

Amino acids.

Genetic engineering has impacted amino acid production through the use of the following strategies: (1) amplification of a rate-limiting enzyme pathway; (2) amplification of the first enzyme after a branch point; (3) cloning of a gene encoding an enzyme with more or less feedback regulation; (4) introduction of a gene encoding an enzyme with a functional or energetic advantage as a replacement for the normal enzyme; and (5) amplification of the first driving enzyme from central metabolism to increase carbon flux in the pathway followed by sequential removal of bottlenecks caused by the accumulation of intermediates.

Transport mutations have also become useful, that is, a mutation that reduces amino acid uptake allows for enhanced excretion and lower intracellular feedback control. This has been especially useful in the production of tryptophan and threonine. In cases where excretion is mediated by transporters, increased activity of these transporter enzymes increases amino acid production.

Other compounds.

Nucleosides. Genetic engineering of the inosine monophosphate (IMP) dehydrogenase gene in a B. subtilis strain that produces 7 gl−1 desirable guanosine and 19 gl−1 undesirable inosines changed the production to 20 gl−1 guanosine and 5 gl −1 inosine. Guanosine is used to produce guanosine monophosphate (GMP), a powerful flavouring agent.

Carotenoids. Carotenoids were overproduced by the introduction of Erwinia uredovora carotenoid gene clusters into E. coli and overexpression of E. coli deoxyglucose phosphate synthase, the key enzyme of the non-mevalonate isoprenoid biosynthetic pathway zeaxanthin at 0.6 mg g−1.

Glucosamine. Glucosamine is used for osteoarthritis and is produced by acid hydrolysis of chitin from shellfish waste. Since many patients have shellfish allergies, a microbial source is desirable. Metabolic engineering of E. coli produced a process that produced 17 gl−1 of glucosamine. In this strain, glucosamine synthase was overexpressed, glucosamine-degrading genes were inactivated, and glucosamine inhibition of glucosamine synthase was decreased. by mutational modification of the enzyme through error-prone PCR. Overexpression of a heterologous glucosamine-6-P-N acetyltransferase produced a strain that produces 110 g l -1 of N-acetylglucosamine which is readily converted to glucosamine by mild acid hydrolysis.

Solvents. Cloning it’s as (acetone) ADC operon genes (encoding acetoacetate decarboxylase), and CTF and CTF (two genes encoding coenzyme A transferase) into a plasmid containing the ADC promoter in Clostridium acetobutylicum resulted in a 95% increase % in the production. The increases were 95% in acetone production, 37% in butanol, 90% in ethanol, 50% yield of solvent from glucose, and 22-fold lower production of undesirable acids. The introduction of the acetone operon of C acetobutylicum in E. coli led to the high production of acetone by the latter.

Cusabio Signal Transduction Recombinants

Product details

Purity: >85% (SDS-PAGE)

Destination names: STAM

Product name: Signal Transduction Recombinants

Uniprot No.: Q92783

Alternative Names

DKFZp686J2352; HSE1 homologue; OTTHUMP00000019237; signal transducer adapter molecule 1; signal transducing adapter molecule (SH3 domain and ITAM motif) 1; STAMS 1; STAM; STAM-1; STAM1_HUMAN

Species: Homo sapiens (Human)

Expression Region: 2-540

Protein length: Total length of the mature protein

Label information

The following labels are available.

  • N-terminus His-tagged
  • Without tags
  • The type of label will be determined during the production process. If you have specified a tag type, let us know and we will develop the specified tag preferentially.

Form: Lyophilized powder

Buffer before lyophilization: Tris/PBS based buffer, 6% trehalose, pH 8.0

Reconstitution

We recommend that this vial be briefly centrifuged before opening to bring the contents to the bottom. Reconstitute protein in sterile deionized water at a concentration of 0.1-1.0 mg/mL. We recommend adding 5-50% glycerol (final concentration) and an aliquot for long-term storage at -20℃/-80℃. Our final default glycerol concentration is 50%. Customers could use it for reference.


Storage Conditions

Store at -20°C/-80°C upon receipt, need to be aliquoted for multiple uses. Avoid repeated cycles of freezing and thawing.

Shelf life

Shelf life is related to many factors, storage condition, buffer ingredients, storage temperature and the stability of the protein itself. Generally, the shelf life of the liquid form is 6 months at -20°C/-80°C. The shelf life of the lyophilized form is 12 months at -20°C/-80°C.

Delivery time

The delivery time may differ depending on the way or location of purchase, consult your local distributors for the specific delivery time.

Notes

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Cusabio Research Recombinants

Description

For more than 14 years, the CUSABIO Protein Expression Platform has established five Research recombinant expression systems from prokaryotes (E.coli) to eukaryotes (insect baculovirus, mammalian cells and yeast), and has also created a protein expression system Unique in vitro E.coli, which allows expressing transmembrane proteins that are normally quite difficult to express. In addition, the CUSABIO protein quality control department owns a professional technical team, equipped with advanced experimental apparatus, to ensure that each protein has a complete and high-quality COA report. CUSABIO purified proteins exceed 90% purity as detected by SDS-PAGE analysis.

We currently have 67 native proteins, 100 small molecule antigens, 640 active proteins, more than 4,400 recombinant proteins in stock, more than 8,900 recombinant proteins developed, more than 13,000 cDNA clones, more than 36,000 transmembrane proteins, more than 500,000 semi-custom recombinant proteins and we could also provide risk-free protein expression service and gene and oligo synthesis service. All these products belong to our Line of Protein Products.

Why choose us?

1. 100% risk-free performance guaranteed

CUSABIO protein products are carefully validated under strict quality control standards to ensure performance. If the product doesn’t work as promised in the manual, just contact us before the expiration date for technical support, replacement or refund.

2. Strict quality control process

The quality of our proteins is the cornerstone of our ability to serve our customers. For this reason, we invest enormous resources in the development of proteins, validating their application, managing, controlling and improving quality. Each protein will go through our standardized quality control process before shipping.

  • Protein concentration detection
  • molecular detection
  • purity detection
  • Endotoxin detection
  • Detection of biological activity (This procedure only applies to proteins with validated activity)
  • Sequence Accuracy

3. Customer Testimonials

I hope this email finds you well. I recently ordered 50ug of Human Protein Carbonic anhydrase 9 (CA9) and I am very pleased with it. We have ordered this protein 5 times in total and all batches perform well. Now we would like to order 10mg and we think the new lot will also do well in our detection.

4. Characteristics of the five expression systems

We have five recombinant expression systems, including yeast, E. coli, baculovirus-infected insect cell, mammalian cell, and cell-free (E. coli in vitro). Different expression systems have various characteristics and are suitable for expressing different proteins, which can satisfy different experimental requirements of researchers. Here is an introduction to the characteristics of five expression systems that might help you choose a suitable system.

5. Multiple Labels for Recombinant Protein

We could provide multiple labels for each protein to meet the different needs of different customers. Here we list the possible tag types for each expression system.

6. Bulk order

  • Capacity

Large fermentation tanks (50L, 500L) allow us to produce proteins on a large scale. We have successfully completed industrial bulk orders for 100mg, 200mg and 500mg.

  • Order application

You can use the protein name/catalogue number/alias/abbreviations/Uniprot number to search for your desired protein in the above search bar, which contains millions of proteins, then you can request the quotation via live chat or send your request to protein1@cusabio. com. If you can’t search for the protein of your interest, please fill in the “Custom Protein Request Form” online, your information will be strictly protected and will not be disclosed to third parties, we will reply to you by email within 24 hours.

7. Professional R&D team

Our company has an R&D team made up of scientists with doctoral and master’s degrees. More than 60% of the total number of employees are in the technical service team, including 20% ​​with PhD degrees and 40% with Master’s degrees; The technical elites are from recognized national institutions, with years of experience in protein development.

8. Animal free

CUSABIO is pleased to inform you that we have developed our line of animal-free recombinant proteins, which drastically minimize variable factors and the possible contamination of mammalian pathogens during the production process. These animal-free proteins are produced in animal-free media, and the purification kit is also free of animal components. Animal-free recombinant protein is worth owning!

9. Good Manufacturing Practice (GMP) Grade Proteins

  • 4000㎡ research laboratories
  • 2000㎡ GMP level production workshop

10. The number of new products

Our protein expression platform has established five prokaryotic to eukaryotic recombinant expression systems and has also built a cell-free expression system. We also established a special and independent protein quality control department, which meets the quality standard of the international protein market, to detect purity, activity, endotoxin level, etc. of the proteins. With our professional R&D team, we can develop and produce more than 2700 proteins every year.

11. Multiple delivery forms

  • Liquid form

The default delivery form is liquid form. If the customer has demand for freeze-dried form, please note this requirement when placing the order.

  • Lyophilized powder

Relatively speaking, the lyophilized form will be more stable than the liquid form and the shelf life will be longer. But freeze-drying can damage the protein structure and can affect the activity of some proteins.

Additional services

1. Label removal service

  • If you need to remove the tag, please contact us in advance; otherwise, we will not remove the tag.
  • Not all protein tags can be removed, as some proteins will be highly unstable after tag removal.
  • If we manage to remove the label, we will charge an additional cost.
  • If we are unable to remove the label, we will not charge any additional costs.
  • Generally, the delivery time will be extended by 2-3 days.

2. Western Transfer Service

  • We could offer Western Blot service to label antibodies for free. If the customer has a demand, please provide this information when placing the order.
  • Generally, the delivery time will be extended by 2-3 days.
  • The WB detection result will be displayed in COA.

Novel Coronavirus (SARS-CoV-2) and Influenza A/B Virus RT-qPCR Detection Kit

Expected use

The SARS-CoV-2/Influenza A&B/RSV RT-qPCR Combo Kit is CE marked, in vitro diagnostic real-time reverse transcriptase PCR (RT-PCR) assay intended to be used for the identification and quantification of COVID-19 viral RNA extracted from Nasopharyngeal swabs and/or oropharyngeal swabs. The assay is designed to be used with designated extraction systems and PCR platforms. The combined SARS-CoV-2/Influenza A&B/RSV RT-qPCR Kit (CE IVD) assay is intended for use by specifically instructed and trained qualified and trained clinical laboratory personnel in real-time PCR techniques and in vitro diagnostic procedures.

Purpose, Scope and Users

SARS-CoV-2 has initially named the 2019 novel coronavirus (2019-nCoV) and was identified by Chinese authorities after an outbreak of pneumonia in December 2019 in Wuhan, Hubei province, China. The WHO declared an international health emergency on January 31, 2020. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend random testing for the asymptomatic population and testing for anyone with symptoms of samples collected from the upper airways and/or lower airways specimens for the identification of SARS-CoV-2 and other respiratory viruses, such as influenza and RSV. RT-qPCR is the gold standard method to identify active infections.

The NIPD Genetics Combined SARS-CoV-2/Influenza A&B/RSV RT-qPCR Kit is a Multiplex real-time RT-qPCR assay for the direct qualitative detection of RNA from 4 viruses: the new coronavirus (SARS-CoV-2), influenza A, influenza B and respiratory A/B syncytial virus (RSV A/B) from human respiratory specimens collected through the Nasopharyngeal and/or oropharyngeal swab method. Validation was performed on the QIAquant 96 5plex real-time PCR instrument (230 V) Real-time PCR detection system. This test can distinguish between influenza A and B subtypes, but not differentiate between RSV A and B. RNA is isolated from respiratory samples, reverse transcribed and amplified using RT-qPCR and detected with four fluorescent dye probes, allowing multiplexing and co-detection by sample reaction.

Fundamental reason

Diagnosis of the aforementioned viruses can be challenging due to the likeness of the symptoms. However, discriminatory and early diagnosis is important for the disease management and treatment, therefore, real-time PCR assay can be a sensitive method and reliable method to detect SARS-CoV-2, influenza A/B and RSV viruses. NIPD Genetics is not responsible for the outcome of a patient’s treatment if the results are being used to guide the medical treatment of health professionals.

Quality control and validity of the results

SARS-CoV-2/Influenza A&B/RSV RT-qPCR Combo Kit Contains Positive Results (PTC) and negative template controls (NTC) to be able to control the PCR amplification. Both of them controls should be included in each run for proper quality control, interpretation of results, and for the results to be considered valid.

Introduction

  • Coronaviruses

are single-stranded, positive-sense, non-segmented RNA viruses. They belong to the Coronaviridae family. They are the largest known RNA viruses with genomes ranging between 27 and 31.5 kb. There are six species of coronaviruses known to causes human diseases 229E, OC43, NL63, HKU1, MERS-CoV, and SARS-CoV. SARS-CoV-2, named as a 2019 novel coronavirus (2019-nCoV) is responsible for the current pandemic that affects millions of people around the world. The virus is transmitted from human to human through respiratory droplets by direct or indirect contact.

Symptoms of SARS-CoV-2 can appear 2 to 14 days after exposure to the virus and at most common symptoms are fever, dry cough, fatigue. Less common symptoms include aches and pains, nasal congestion, sore throat, diarrhoea, loss of smell (anosmia) or loss of taste (ageusia), etc. The strongest and most consistent evidence of increased risk comes from patients with a BMI greater than 30 kg/m2, type 2 diabetes mellitus and with underlying lung and heart conditions, who are more likely to develop complications and require ICU admission and oxygen support.

  • Influenza viruses

are negative-sense viruses that belong to the Orthomyxoviridae family. The most common influenza viruses that infect humans are influenza A and B. The most common symptoms include fever, cough, sore throat, nasal congestion, and discharge that can lead to more serious complications of pneumonia. age and underlying pulmonary medical conditions (eg, COPD, IPF, asthma, smokers) increase the risk of developing complications.

  • Human respiratory syncytial viruses (RSV)

are non-segmented, negative, viruses with single-stranded linear RNA genome belonging to the Paramyxoviridae family. RSV causes respiratory infections in humans, including bronchitis, pneumonia, and chronic obstructive pulmonary infections. Common symptoms include runny nose discharge, low-grade fever, cough, sore throat, headache, and wheezing. All of the aforementioned viruses are transmitted between humans in three ways: (1) directly contact with infected people; (2) by contact with contaminated objects (such as toys, doorknobs); and (3) by inhalation of virus-laden aerosols.

General rules

1. Transport and storage conditions

Reagents are shipped and stored at -20°C until the expiration date, as indicated on the label. To minimize freeze-thaw cycles and preserve the integrity of the PTC, we recommend aliquoting and storing at -20°C. All components must be kept away from sunlight.

2. Training requirements

Testing for the presence of viral RNA should be performed in a laboratory equipped with trained personnel to carry out the pertinent technical procedures according to the Laboratory standards of the Occupational Safety and Health Administration (OSHA). Refer to the World Health Organization Interim Guidance on Laboratory Biosafety and the Centers for Disease Control and Prevention (CDC) Guidelines for Interim Laboratory Biosafety guidelines for the handling and processing of samples associated with SARS-CoV-2.

3. Precautions and Recommendations

  • The procedures in this manual must be followed as described. any deviation may result in assay failure or cause erroneous results and interpretation.
  • GLP is required to ensure kit performance, with care taken to avoid contamination of kit components. Components believed to have been converted Contaminated should be disposed of as standard laboratory waste in a sealed container ziplock bag or plastic bag.
  • Sample samples must be collected, transported, and stored in accordance with appropriate laboratory guidelines. For more information, see the CDC3 guidelines for “Interim Guidelines for the Collection, Handling, and Analysis of Clinical Specimens for COVID-19″.
  • Specimens must be processed within 4 hours of collection. Samples that will be processed after the 4-hour post-harvest window should be stored between 2-8°C for up to 72 hours.
  • Thaw reagents at room temperature before use and keep on ice.
  • Shelf life of reagents is 12 months when properly stored.
  • Do not use reagents past the expiration date. After the expiration date, the quality of the warranty is no longer valid.
  • Do not mix reagents from different kits and/or lots and/or from another supplier.
  • Wear personal protective equipment (PPE), such as disposable gloves, goggles, and mask during sample collection and processing.
  • Handle all specimens as if they were infectious using GLP and Safety Standards and Occupational Health Administration (OSHA) Laboratory Standard (29 CFR 1910.1450).
  • Carry out all manipulations of possible live virus samples within a class II (or higher) biological safety cabinet.
  • Dispose of waste in accordance with local, state and federal regulations.
  • Regular decontamination of commonly used equipment is recommended, especially micropipettes and work surfaces with at least 70% (v/v) ethanol. Yes is working with RNA, to avoid degradation, it is recommended for the processing area banks to clean with RNase AWAY ® or 10% freshly prepared Bleach.
  • Consult the safety data sheet (SDS) before using this kit, which is available on request.
  • Please refer to the reference manual of each real-time qPCR instrument for additional information, warnings, precautions, procedures and data analysis.

PROTIA Food IgG

The Myth of IgG Food Panel Testing

IgGEs Food Panel Test Very common for patients to feel they have food allergies or food intolerances/sensitivities. These terms or labels are often used interchangeably. However, it is important to understand that allergies are very different from intolerances or sensitivities. There are excellent materials on this website to help you distinguish between the two. With a food allergy, the body mounts an immune response to the food, and this can be dangerous. With an intolerance or sensitivity, the body may simply not be processing or digesting food properly and this is not really dangerous (although it can obviously be uncomfortable).

More classic food intolerances (such as lactose intolerance) cause patients to experience bloating, fullness, stomach pain, gas, and/or diarrhoea when they eat too much food. This is because the body is not digesting food properly, leading to a buildup of air and gases in the stomach and intestines. Other patients experience headaches, fatigue, “brain fog” or stomach pain with various foods or additives/preservatives. Oftentimes, patients feel that multiple foods may be causing these symptoms and are hoping to find a single test that will tell them exactly which foods to avoid so they can simply feel better.

Unfortunately, there is no single test that can give you this answer. One test that claims to be able to diagnose food sensitivities and is commonly available in the food IgG test. This test, offered by several companies, reports IgG levels for multiple foods (typically 90 to 100 foods with a single panel test) and claims that eliminating foods with high IgG levels can lead to improvement in multiple symptoms. Some websites even report that diets using this test can help with symptoms of irritable bowel syndrome, autism, cystic fibrosis, rheumatoid arthritis, and epilepsy.

It is important to understand that this test has never been scientifically proven to do what it claims to do. The scientific studies provided to support the use of this test are often out of date, in unaccredited journals, and many have not even used the IgG test in question. The presence of IgG is probably a normal response of the immune system to food exposure. In fact, higher levels of IgG4 to foods may simply be associated with tolerance to those foods.

COVID-19 Ag

COVID-19 Ag Rapid Test

The COVID-19 Rapid Antigen Test, a lateral flow chromatographic immunoassay, looks for protein fragments of the virus and thus its direct physical presence in the body. It is performed using a swab from the oral cavity or from the nasopharynx. This is extracted into a buffer solution and then pipetted into the test cassette. A qualitative result is ready in less than 20 minutes.

The diagnostic sensitivity is 97.56% (ct value: 20 – 30) and the diagnostic specificity is >99.9%. That means positive antigen test results are highly accurate. However, as there is always a residual risk of a false negative result if, in doubt, a PCR test should be performed to confirm negative results. The choice between antibody, antigen, and PCR testing is not a one or other decision. Rather, the best tactic is a combined application.

Test properties:

  • Optimized testing process
  • High specificity (>99.9%)
  • Highly sensitive with high viral loads: 97.56% (ct value: 20 – 30)
  • Easy to use
  • Fast and reliable test results in just 15 minutes
  • Testing can be performed using nasal, nasopharyngeal, and oropharyngeal specimens.
  • It can be stored at room temperature.
  • All test components, including sterile swabs, are included.
  • No cross-reactivity with seasonal coronaviruses (such as hCoV-229E, -HKU1, -NL63, and -OC43) or influenza viruses (such as influenza A/B)

Importance of the antigen test

While the COVID-19 IgG/IgM Rapid Test detects the virus indirectly, the COVID-19 Rapid Antigen Test detects it directly by checking for the presence of specific proteins of the SARS-CoV-2 virus. Therefore, antigen detection closes a diagnostic gap. The nucleocapsid (N) protein is ideal for virus detection because it is highly abundant in the virus and specific enough for SARS-CoV-2. It is one of the 4 most important structural proteins of the virus and is involved in the replication, transcription and packaging of the viral genome.

The COVID-19 Rapid Antigen Test is a lateral flow chromatographic immunoassay for the qualitative detection of SARS-CoV-2 viral nucleoprotein antigens in human nasal- and oropharyngeal specimens. The test is intended to be used as an aid in the diagnosis of SARS-CoV-2 infections. It should be noted that the concentration of viral nucleoprotein antigens may vary during the course of the disease and may fall below the detection limit of the test. The possible infectiousness of test subjects cannot be excluded based on negative test results.

AGS 8830

Description

This product uses “real-time fluorescent quantitative PCR technology” combined with self-developed “real-time dynamic precision temperature control technology”, which can be used in various fluorescent quantitative PCR detection projects to achieve accurate detection. rapid nucleic acid With powerful features and flexible operation, DNA and RNA PCR amplification and detection experiments can be completed in a compact and portable environment.

Using a special reverse anti-pollution open cap design, can effectively prevent contamination caused by accidental bursting of the hot cap, simplify the experimental operation process, and combine with efficient and fast PCR reagents to provide a complete solution for SARS. -CoV- 2 detection and other projects.

Additional Information

1. Equipment Features

  • ORF1ab and N gene
  • RNase P as an internal control
  • CT cutoff: ≤30
  • LoD: 500 copies/mL
  • Throat smear or sputum
  • This kit can also be compatible with ABI7500, BIORAD CFX96, AGS4800

2. Operation Steps (Combine with Nucleic Acid Releasing Reagent DA0940)

  • Sampling and inactivation
  • Rock and rest for 5 min, then centrifuge
  • Add the extracted sample to the PCR tubes with PCR reagent
  • Perform PCR, within 0.5 hours to obtain the result

Security

The following basic safety measures should be observed during the operation, maintenance and repair of the instrument. If the notes, warnings or cautions specified in the manual are neglected, the basic protection provided by the instrument may be affected. Meanwhile, it may also damage the security level of the design and manufacture of instruments and the intended scope of application.

It is not allowed to change the parts of the instrument without permission, and the inspection and maintenance of the instrument must be completed by engineers licensed by Hangzhou AnYu Technologies Co., Ltd. If the equipment is not used in the manner specified in this manual, the protection provided by the equipment may be damaged

Instrument maintenance

The wells and hot cap of the instrument should be periodically cleaned with special brushes bathed in a little absolute alcohol to guarantee complete contact between tubes and wells and high thermal conductivity while free of pollution. Use a soft cloth to do daily maintenance to clean the surface and wells. If there is any stain on the surface, you can clean it with a dust-free cloth with 75% alcohol. Do not use chlorine disinfectants, moisturizers, antibacterials soaps, aromatic solutions, propanol or isopropanol to clean the equipment, as they are types of cleaning or sanitizing agent is easy to have a chemical reaction with parts of the equipment or materials contained in the equipment and cause danger.

Perform only the maintenance mentioned in this manual. Before using any cleaning and disinfection method not described in this document, please contact the technical support personnel of the Company or authorized agency to ensure that the method used will not damage the instrument. If you have any questions on the compatibility of disinfectants or cleaning agents with pieces of equipment or materials contained in the equipment, consult the Company or an authorized agency.

PaxView SARS-CoV-2

Expected use

  • In vitro diagnostic medical devices: IVD
  • Diagnosis of SARS-CoV-2 infection
  • Respiratory samples such as oropharyngeal or nasopharyngeal swabs

Features and Benefits

  • One-step RT-PCR in a single tube
  • Since the human RNase P gene is used as an internal control, it is possible to check whether the test result is correct, accurate or not by monitoring the whole testing process such as sample collection, RNA extraction and RT-PCR
  • High sensitivity and high specificity – Limit of detection (LoD): 1 copy/µl (5 copies/reaction)
  • Simple and easy-to-use procedure
  • Accurate diagnosis regardless of SARS-CoV-2 variants (Alpha, Beta, Gamma, Delta, Omicron)
  • The result report is sent to the laboratory by providing the reporting system (viewer program)

Product Principle

  • real-time RT-PCR
  • Target genes: RdRp gene and N gene
  • Kit includes human targeted primer and probe set RNase P gene that serves as an internal positive control for the validation of complete procedures, including sample collection, RNA purification and PCR

Presentation Features

1. Analytical Sensitivity (Detection limit)

  • Limit of detection (LoD) : 1 copy/µl (5 copies/reaction)

2. Precision

  • Repeatability within CV 3%
  • Reproducibility within CV 2%

3. Transfer Prevention pollution

  • Prevention of transfer contamination by use of UDG

4. Analytical Specificity (cross-reactivity)

  • No cross-reactivity with 26 tested respiratory pathogens

5. Analytical Specificity (interference)

  • No interference with 9 tested interfering substances

SARS-CoV-2 virus variant detection test

  • Kit used: PaxView® SARS-CoV-2 real-time RT-PCR kit
  • Equipment Used: CFX96 (Bio-Rad)
  • The specimen used: SARS-CoV-2, SARS-CoV-2 variants (alpha, beta, gamma, delta)
  • Specimen source: NCCP (National Culture Collection of Pathogens) of Korea Disease Control and Prevention Agency
  • Test method: test with a 1/10 serial dilution of each virus

Physicians’ knowledge of genetics and genetic tests.

Physicians' knowledge of genetics and genetic tests.
Questionnaires had been mailed in 1991 to 1,795 major care physicians (household physicians, internists, pediatricians, obstetrician-gynecologists) and psychiatrists who had graduated from medical college between 1950 and 1985 (67.6% of the pattern had graduated after 1970) and who had been members of skilled societies. The questions elicited demographic and observe traits in addition to knowledge of genetics ideas and details and consciousness of the provision of genetic exams. To validate the questionnaire, 360 medical geneticists and genetic counselors acquired questionnaires. Statistical evaluation concerned arc-sine operate transformation, t-tests, analyses of variance, F-tests, Tukey’s HSD, and stepwise a number of regression.
A complete of 1,140 (64.8%) of the non-geneticist physicians responded. They appropriately answered a median of 73.9%, SD, 13.9%, of the knowledge objects, in contrast with 94.6%, SD, 4.2%, for the genetics professionals (p < .001). The most important predictors of knowledge had been recency of commencement from medical college and practising in major care specialties by which publicity to genetics issues is probably going. Other important predictors (from most to least essential) had been commencement from a U.S. medical college, willingness to undertake a brand new predictive take a look at earlier than it turns into commonplace observe, not utilizing pharmaceutical firms as a supply of details about new medical practices, and taking a required genetics course in medical college.
The outcomes counsel that knowledge of genetics and genetic exams is growing amongst physicians, significantly amongst more moderen graduates and physicians who’re uncovered to genetics issues of their practices, however deficiencies stay. Although a medical college course in genetics could enhance knowledge, it’s not enough. Greater emphasis is required in any respect ranges of medical schooling to cut back the prospect of doctor error as extra genetic exams turn into out there. DNA testing for home cat ailments and look traits is a quickly rising asset for veterinary drugs.

Approximately 33 genes comprise 50 mutations that trigger feline well being issues or alterations within the cat’s look. A range of industrial laboratories can now carry out cat genetic diagnostics, permitting each the veterinary clinician and the personal proprietor to acquire DNA take a look at outcomes. DNA is definitely obtained from a cat through a buccal swab with an ordinary cotton bud or cytological brush, permitting DNA samples to be simply despatched to any laboratory on this planet. The DNA take a look at outcomes determine carriers of the traits, predict the incidence of traits from breeding applications, and affect medical prognoses and therapies. An total purpose of figuring out these genetic mutations is the correction of the defect through gene therapies and designer drug therapies.

Frontotemporal dementia: genetics and genetic counseling dilemmas.

Frontotemporal dementia (FTD) is a neurodegenerative illness with early signs of persona change and/or language dysfunction. Approximately 40% of people with FTD have a household historical past of dementia; nonetheless, in our expertise, lower than 10% have clear autosomal dominant inheritance. Mutations within the microtubule-associated protein tau (MAPT) gene have been reported in as much as 50% of hereditary instances, however are uncommon besides in households with greater than Three people with FTD. The genetics of FTD is difficult by medical heterogeneity, variable expression, phenocopies, misdiagnoses, and misplaced household histories.
The complexity of FTD genetics and genetic counseling are illustrated utilizing Four case histories. Case 1 demonstrates the problem acquiring a dependable FTD household historical past. Case 2 illustrates how psychiatric phenocopies could make household linkage research troublesome. The lack of genotype and phenotype correlation and points of predictive genetic testing inside FTD households are the topic of case 3, and case Four reveals how regular getting older language difficulties and cognitive adjustments will be misinterpreted when a household historical past of dementia is current.
Physicians seeing sufferers with potential FTD needs to be conscious of the chance of a genetic etiology. A 3-generation household historical past needs to be obtained with consideration to neurologic, psychiatric, and behavioral signs. Variable expression and phenocopies are confounding components when assessing a potential genetic etiology. Referral of the affected person and household for genetic counseling is really useful. The goal of this paper is to allow physicians to acknowledge hereditary patterns and genetic issues of FTD households and to grasp genetic counseling methods.
Physicians' knowledge of genetics and genetic tests.

Genetic range and genetic burden in people.

We talk about classes of genetic range in people. Neutral range, inhabitants variations in frequencies of genetic markers that we expect are invisible to pure choice, gives a passive file of inhabitants historical past however is in any other case of little curiosity in human biology. Genetic variation associated to illness will be separated into mutational noise and variation on account of choice, both ongoing choice else results of a previous atmosphere. We name genetic variation that causes impairment of well being or well-being of particular person people “obvious genetic burden” and variation that has results on health however not well-being “unapparent genetic burden”.

We use “burden” to tell apart these notions from the classical idea of “genetic load” that refers to results on inhabitants health, an idea formulated by Morton et al. We distinguish tailored genes and tailored genotypes: an tailored gene is a gene that will increase health of its bearer both in heterozygous or homozygous state or each, whereas an tailored genotype is a genotype that will increase health of its bearer however shouldn’t be transmitted intact to future generations.

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 280

anti-Cellular Apoptosis Susceptibility

YF-PA23522 50 ul
EUR 334
Description: Mouse polyclonal to Cellular Apoptosis Susceptibility

anti-Apoptosis enhancing nuclease

YF-PA20583 50 ug
EUR 363
Description: Mouse polyclonal to Apoptosis enhancing nuclease

Anti-Bax (Apoptosis Marker) Monoclonal Antibody

M00183 100ug/vial
EUR 397
Description: Mouse Monoclonal Bax (Apoptosis Marker) Antibody. Validated in IF, IHC and tested in Human, Monkey.

Anti-Apoptosis inhibitor 5/API5 Antibody

PA1009 100ug/vial
EUR 334

Histone H3 Phosphorylation Antibody Panel Pack

C10014 3 x 25 µg
EUR 628.55
Description: kits suitable for this type of research

Anti-Apoptosis repressor with CARD/NOL3 Antibody

PA1793 100ug/vial
EUR 294

Anti-Prostate Apoptosis Response Protein-4 Antibody

A03637 100ul
EUR 397
Description: Rabbit Polyclonal Prostate Apoptosis Response Protein-4 Antibody. Validated in IHC, WB and tested in Human, Mouse, Rat.

anti-Cellular Apoptosis Susceptibility (2B7)

LF-MA10074 100 ug
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

Anti-Cellular Apoptosis Susceptibility (2C10)

YF-MA10197 100 ug
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

Anti-Cellular Apoptosis Susceptibility (2F4)

YF-MA10198 100 ug
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

Anti-Cellular Apoptosis Susceptibility (3F8)

YF-MA10199 100 ug
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

Anti-Cellular Apoptosis Susceptibility (3D8)

YF-MA10200 100 ug
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

Anti-Apoptosis inhibitor 5 (1C2)

YF-MA11077 100 ug
EUR 363
Description: Mouse monoclonal to Apoptosis inhibitor 5

Anti-Cellular Apoptosis Susceptibility (1E4)

YF-MA12554 100 ug
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

Anti-Cellular Apoptosis Susceptibility (1E4)

YF-MA12555 200 ul
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

Anti-Cellular Apoptosis Susceptibility (2C10)

YF-MA12556 200 ul
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

Anti-Cellular Apoptosis Susceptibility (2F4)

YF-MA12557 200 ul
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

Anti-Cellular Apoptosis Susceptibility (3F8)

YF-MA12558 200 ul
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

Anti-Cellular Apoptosis Susceptibility (1C1)

YF-MA12559 100 ug
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

Anti-Cellular Apoptosis Susceptibility (1C4)

YF-MA12560 100 ug
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

Anti-Cellular Apoptosis Susceptibility (1C4)

YF-MA12561 200 ul
EUR 363
Description: Mouse monoclonal to Cellular Apoptosis Susceptibility

EnzyFluo NFkB Phosphorylation Assay Kit

ENFKB-100 100
EUR 545
Description: For quantitative fluorescent immunoenzymatic assay of NFκB phosphorylation status in cultured cells. Method: FL360/450nm, 530/585nm. Samples: cells. Species: human, mouse. Procedure: 3 hrs (hands-on time). Size: 100 tests.

EnzyFluo AMPK Phosphorylation Assay Kit

EAMPK-100 100
EUR 545
Description: For quantitative fluorescent immunoenzymatic assay of AMPK phosphorylation status in cultured cells. Method: FL360/450nm, 530/585nm. Samples: cells. Species: human, mouse, rat. Procedure: 3 hrs (hands-on time). Size: 100 tests.

EnzyFluo ERK Phosphorylation Assay Kit

EERK-100 100
EUR 556
Description: For quantitative fluorescent immunoenzymatic assay of ERK1/2 phosphorylation status in cultured cells. Method: FL360/450nm, 530/585nm. Samples: cells. Species: human, mouse, rat.. Procedure: 3 hrs (hands-on time). Size: 100 tests.

Chemical phosphorylation amidite, 5 g

62560 5 g
EUR 1426

Chemical phosphorylation amidite, 250 mg

22560 250 mg
EUR 193

Chemical phosphorylation amidite, 1 g

42560 1 g
EUR 349

Calcium-Binding Tyrosine Phosphorylation-Regulated Protein (CABYR) Antibody

20-abx111304
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul

Calcium-Binding Tyrosine Phosphorylation-Regulated Protein (CABYR) Antibody

abx340188-100ug 100 ug
EUR 391

Calcium-Binding Tyrosine Phosphorylation-Regulated Protein (CABYR) Antibody

20-abx148788
  • EUR 425.00
  • EUR 342.00
  • 100 ug
  • 50 ug

Calcium-Binding Tyrosine Phosphorylation-Regulated Protein (CABYR) Antibody

abx231170-100ug 100 ug
EUR 509

Chemical Phosphorylation Reagent I (CPR I)

6001 1 g
EUR 480

Human Glycogen phosphorylation(GP)ELISA Kit

QY-E05461 96T
EUR 361

Apoptosis-enhancing nuclease antibody

22725-100ul 100ul
EUR 390

Cellular Apoptosis Susceptibility Antibody

49774-100ul 100ul
EUR 333

Cellular Apoptosis Susceptibility Antibody

49774-50ul 50ul
EUR 239

Cellular Apoptosis Susceptibility Antibody

abx030969-400ul 400 ul
EUR 523

Cellular Apoptosis Susceptibility Antibody

abx030969-80l 80 µl
EUR 286

Apoptosis enhancing nuclease antibody

70R-13466 100 ul
EUR 457
Description: Affinity purified Rabbit polyclonal Apoptosis enhancing nuclease antibody

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A) Antibody

20-abx128317
  • EUR 425.00
  • EUR 133.00
  • EUR 1205.00
  • EUR 578.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (DYR1A) Antibody

20-abx119074
  • EUR 314.00
  • EUR 98.00
  • EUR 398.00
  • EUR 495.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 2 (DYRK2) Antibody

abx122510-100ug 100 ug
EUR 391

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1B (DYRK1B) Antibody

20-abx112184
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 4 (Dyrk4) Antibody

20-abx112185
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 2 (DYRK2) Antibody

20-abx320190
  • EUR 300.00
  • EUR 244.00
  • 100 ul
  • 50 ul

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 4 (DYRK4) Antibody

20-abx323377
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1B (DYRK1B) Antibody

20-abx003172
  • EUR 411.00
  • EUR 592.00
  • 100 ul
  • 200 ul

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1B (DYRK1B) Antibody

20-abx133669
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 4 (DYRK4) Antibody

20-abx147533
  • EUR 425.00
  • EUR 342.00
  • 100 ug
  • 50 ug

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A) Antibody

20-abx135705
  • EUR 411.00
  • EUR 592.00
  • EUR 182.00
  • EUR 314.00
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 2 (DYRK2) Antibody

20-abx005313
  • EUR 411.00
  • EUR 592.00
  • EUR 182.00
  • EUR 314.00
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A) Antibody

20-abx009320
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1B (DYR1B) Antibody

20-abx013869
  • EUR 314.00
  • EUR 98.00
  • EUR 398.00
  • EUR 495.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 2 (DYRK2) Antibody

abx025430-400ul 400 ul
EUR 523

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 2 (DYRK2) Antibody

abx025430-80l 80 µl
EUR 286

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 2 (DYRK2) Antibody

abx033457-400ul 400 ul
EUR 523

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 2 (DYRK2) Antibody

abx033457-80l 80 µl
EUR 286

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 3 (DYRK3) Antibody

abx033458-400ul 400 ul
EUR 523

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 3 (DYRK3) Antibody

abx033458-80l 80 µl
EUR 286

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 4 (DYRK4) Antibody

abx033459-400ul 400 ul
EUR 523

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 4 (DYRK4) Antibody

abx033459-80l 80 µl
EUR 286

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A) Antibody

abx033472-400ul 400 ul
EUR 523

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A) Antibody

abx033472-80l 80 µl
EUR 286

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A) Antibody

abx033473-400ul 400 ul
EUR 523

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A) Antibody

abx033473-80l 80 µl
EUR 286

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Dyrk1a) Antibody

abx031012-400ul 400 ul
EUR 523

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Dyrk1a) Antibody

abx031012-80l 80 µl
EUR 286

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1B (Dyrk1b) Antibody

abx028179-400ul 400 ul
EUR 523

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1B (Dyrk1b) Antibody

abx028179-80l 80 µl
EUR 286

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 4 (Dyrk4) Antibody

abx028415-400ul 400 ul
EUR 523

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 4 (Dyrk4) Antibody

abx028415-80l 80 µl
EUR 286

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A) Antibody

abx431220-200ul 200 ul
EUR 384

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1B (DYRK1B) Antibody

abx232592-100ug 100 ug
EUR 481

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 4 (DYRK4) Antibody

abx232593-100ug 100 ug
EUR 509

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A) Antibody

20-abx176210
  • EUR 1233.00
  • EUR 592.00
  • 1 mg
  • 200 ug

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A) Antibody

20-abx176211
  • EUR 1233.00
  • EUR 592.00
  • 1 mg
  • 200 ug

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A) Antibody

20-abx172170
  • EUR 857.00
  • EUR 439.00
  • 1 mg
  • 200 ug

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 4 (DYRK4) Antibody

20-abx301717
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 3 (DYRK3) Antibody

20-abx303688
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A) Antibody

20-abx329453
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1B (DYRK1B) Antibody

abx331760-100ul 100 ul
EUR 425

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1B (DYRK1B) Antibody

20-abx325860
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug

Apoptosis Inhibitor

A1930-10 10 mg
EUR 142
Description: M50054, 2,2'-methylenebis (1,3-cyclohexanedione), is a novel inhibitor of apoptosis. [1] In human Fas-expressing WC8 cells, M50054 inhibited apoptosis by soluble human Fas ligand in vitro cell death assay.

Apoptosis Inhibitor

A1930-100 100 mg
EUR 456
Description: M50054, 2,2'-methylenebis (1,3-cyclohexanedione), is a novel inhibitor of apoptosis. [1] In human Fas-expressing WC8 cells, M50054 inhibited apoptosis by soluble human Fas ligand in vitro cell death assay.

Apoptosis Inhibitor

A1930-25 25 mg
EUR 235
Description: M50054, 2,2'-methylenebis (1,3-cyclohexanedione), is a novel inhibitor of apoptosis. [1] In human Fas-expressing WC8 cells, M50054 inhibited apoptosis by soluble human Fas ligand in vitro cell death assay.

Apoptosis Inhibitor

A1930-5.1 10 mM (in 1mL DMSO)
EUR 108
Description: M50054, 2,2'-methylenebis (1,3-cyclohexanedione), is a novel inhibitor of apoptosis. [1] In human Fas-expressing WC8 cells, M50054 inhibited apoptosis by soluble human Fas ligand in vitro cell death assay.

Apoptosis Inhibitor

A1930-S Evaluation Sample
EUR 81
Description: M50054, 2,2'-methylenebis (1,3-cyclohexanedione), is a novel inhibitor of apoptosis. [1] In human Fas-expressing WC8 cells, M50054 inhibited apoptosis by soluble human Fas ligand in vitro cell death assay.

Apoptosis inhibitor

2783-25
EUR 457

Apoptosis inhibitor

2783-5
EUR 153

Rabbit Dual specificity tyrosine- phosphorylation- regulated kin

ELI-27714Ra 96 Tests
EUR 928

Apoptosis Inhibitor 5 (API5) Antibody

20-abx128094
  • EUR 425.00
  • EUR 133.00
  • EUR 1205.00
  • EUR 578.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Factor Related Apoptosis (FAS) Antibody

20-abx128470
  • EUR 356.00
  • EUR 133.00
  • EUR 996.00
  • EUR 495.00
  • EUR 300.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Factor Related Apoptosis (FAS) Antibody

20-abx129940
  • EUR 453.00
  • EUR 133.00
  • EUR 1288.00
  • EUR 620.00
  • EUR 342.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Factor Related Apoptosis (FAS) Antibody

20-abx130140
  • EUR 398.00
  • EUR 133.00
  • EUR 1066.00
  • EUR 523.00
  • EUR 300.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Factor Related Apoptosis (FAS) Antibody

20-abx130850
  • EUR 411.00
  • EUR 133.00
  • EUR 1163.00
  • EUR 565.00
  • EUR 314.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Bifunctional Apoptosis Regulator (BFAR) Antibody

20-abx320837
  • EUR 439.00
  • EUR 328.00
  • 100 ul
  • 50 ul

Balanced polymorphisms by which the heterozygote is superior in health could generate most tailored genotypes. In the face of main speedy environmental change tailored genotypes seem first however over time they’re changed by tailored genes. The presence of tailored genotypes is an effective indication of current environmental change: for instance, there are apparently many polymorphisms in home animals of this nature, responses to domestication, and many fewer in wild animals (and in people). We distinguish penalties of genetic range for health, related to evolution, and penalties for well-being, related to drugs and public well being.